The FDA has already started to take initiatives to integrate personalised medicine into their regulatory policies. An FDA report in October 2013 entitled, "''Paving the Way for Personalized Medicine: FDA's role in a New Era of Medical Product Development''," in which they outlined steps they would have to take to integrate genetic and biomarker information for clinical use and drug development.

